Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	17.48B
Revenue (ttm)	2.68B
Net Income (ttm)	130.68M
Shares Out	1.60B
EPS (ttm)	0.08
PE Ratio	132.73
Forward PE	46.02
Dividend	0.01 (0.09%)
Ex-Dividend Date	May 28, 2025

Volume	31,379,264
Average Volume	45,379,182
Open	10.48
Previous Close	10.93
Day's Range	10.48 - 11.09
52-Week Range	9.70 - 18.98
Beta	0.66
RSI	55.47
Earnings Date	Aug 22, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.